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A b s t r a c t  
Quercetin is a ubiquitous plant flavoniod with significant pharmacological and clinical activity. In this 
study we determined to demonstrate the protective role of quercetin against range of mutagens and 
carcinogens in a combination of in vitro and in vivo studies via different mechanisms. Quercetin 
demonstrated significant protective role against sodium azide, benzo(a)pyrene, cyclophosphamide 
monohydrate, methyl methane sulphonate and etoposide compared to other mutagens. Quercetin is 
effective in both in vitro and in vivo test conditions and also in the presence as well as in the 
absence of metabolic activation system (Rat liver S9).  Auto oxidation, antioxidant properties, 
inhibition of pro-mutagens metabolism by CYP1A activity and multiple antimutagenic and adaptive 
responses, mechanisms of quercetin may account for its protective role in cancer prevention. In 
conclusion, the results clearly indicate that quercetin plays a significant role against mutagens that 
act by direct DNA binding (form DNA adducts), pro-mutagens and alkylating agents with free radical 
generation; which could be the rationale for its potent anticancer activity against particular cancer 
types.     
Keywords: Quercetin, adaptive response, cancer, Ames test, chromosomal aberration, cell gene 
mutation  
Introduction 
Cancer is the second leading cause of death with significant 
mortality and morbidity throughout the world. Though molecular 
based disease specific cancer therapy is available, strive for an 
ideal chemo preventive/therapeutic candidate continues. There is 
increasing evidence that bioactive compounds   with antimutagenic 
activity are known to protect cellular components from genotoxic 
damage and prevent diseases. Quercetin is a natural flavonoid 
abundantly present in plant foods. It has significant pharmacological 
and medicinal properties including antioxidant, anti-inflammatory, 
antimutagenic and anticancer activity [1]. 
Its wide clinical activity may suitably correlates with its pleotropic 
activity in target cells/tissues. Quercetin has been shown to possess 
anti tumour effects on several malignant leukemia cell lines such as 
HL-60, K562, NB4 and Jurkat cells and its clinical utility as an 
anticancer drug has been investigated widely [2,3]. In several 
combination studies of quercetin with natural compounds and 
chemotherapy drugs has resulted synergistic effects though the 
exact anticancer mechanism for clinical efficacy is largely unclear 
[4, 5, 6]. However it shows strong antioxidant activity and a 
significant antimutagenic effect was also demonstrated in 
combination with ascorbic acid [7].   
Adaptive response (AR) is a phenomenon, when cells are exposed 
to the lower non mutagenic concentrations of quercetin will become 
resistant to subsequent doses of other mutagens or carcinogens. 
There is limited data available on the adaptive response of 
quercetin, i.e.  Chromosomal aberration test with cultured V79 cells 
[8] and micronucleus test in human peripheral lymphocytes [9] are 
the little evidence to demonstrate. Therefore an inclusive 
assessment in varied test systems with range of 
mutages/carcinoges is required for complete understanding of the 
mechanism. For the demonstration of quercetin mode of action in 
antimutagenicity and adaptive response, a wide range of 
mutagens/carcinogens were selected (Table-1), based on their 
mutagenic properties in varied test systems, mode of action in 
cancer development and clinical significance. 
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Table 1: Selected chemical mutagens and their properties 
Mutagen IARC 
category 
Mode of action (in mutagen city) Distribution/Therapeutic 
importance 
Benzo (a) pyrene (BP) 1 Direct binds to DNA, form DNA-BP adduct Environment  and food 
mutagen 
Cyclophosphamide 
monohydrate (CP) 
1 Alkylating agent: add alkyl group to DNA and 
form free radicals 
Anti cancer drug 
 
Mitomycin C (MMC) 2B DNA cross linking agent Food mutagen 
Methyl methane 
sulphonate (MMS) 
2A Alkylating agent Environment mutagen 
Etoposide (Et) 1 Chromosomal mutation and topoisomerase II 
inhibitor 
Anti cancer drug 
Hydralazine (Hy) 3 DNA damage – point mutations Muscle relaxant 
(Essential medicine) 
Bendamustine (BH) 
hydrochloride   
- Alkylating agent Anti cancer drug 
2 Nitrofluorine (2NF) 2B Point mutations to DNA Reference mutagens 
Sodium azide  (SA) - Point mutations to DNA 
9 Aminoacridine  (9AA) - Point mutations to DNA 
2 Amino anthracene 
(2AA) 
- Indirect mutagen forms DNA adduct 
 
Because a strong correlation exists between genetic damage and 
carcinogenesis, identifying the natural compounds with 
antimutagenic activity could be beneficial in cancer treatment.  
Consequently we determined to investigate antimutagenic 
activity/adaptive response of quercetin using a combination of in 
vitro and in vivo genetoxicity testing standard test battery. These 
tests are routinely employed for regulatory compliance of new 
chemical entities (NCE) in preclinical drug discovery programme. 
The Organisation for Economic Co-operation and Development 
(OECD) guidelines and the International Workshops on Genotoxicity 
Testing (IWGT) recommended protocols were followed for these 
tests [10-13]. These tests include: bacterial reverse mutation 
(Ames) test using histidine dependent Salmonella test strains i.e. 
TA 1537, TA 98, TA 100 and TA 102, chromosomal aberration test 
(CAT) using CHO K1 cell line to detect structural chromosome 
aberrations, cell gene mutation assay (CGM) using L5178Y TK+/- 
cells for the detection of mutagenicity using eukaryotic cell line and 
bone marrow micronucleus test in mice for clastogencity evaluation 
of test chemicals, in vivo.  
It is also extremely important to realize that the main focus of these 
antimutagenicity tests should be towards understanding of the 
mode of action of the compounds and the ability to correlate short 
term results with anticarcinogenicity experiments in animal models 
[14].    
Materials and Methods 
Chemicals and culture media  
Quercetin (6151-25-3), 9-aminoacridine (90-45-9), sodium azide 
(26628-22-8), 2-nitrofluorene (607-57-8), hydralazine (304-20-1), 
etoposide (33419-42-0), methyl methane sulphonate (66-27-3), 
mitomycin-C (50-07-7), 2-aminoanthracene (613-13-8), 
benzo(a)pyrene (50-32-8), bendamustine hydrochloride (3543-75-
7), cyclophosphamide monohydrate (6055-19-2), magnesium 
sulphate(MgSO4.7H2O), citric acid monohydrate, potassium 
phosphate dibasic (K2HPO4), sodium ammonium phosphate, 
(NaHNH4PO4.4H2O), dextrose, L-histidine, D- biotin, sodium 
chloride, sodium dihydrogen phosphate (NaH2PO4), disodium 
hydrogen phosphate (Na2HPO4), D- glucose -6- phosphate, β 
NADP, magnesium chloride, dimethyl sulphoxide, potassium 
chloride, RPMI-1640 medium, Hams F12 K medium, trifluro 
thymidine (TFT), KCl, KH2PO4, NaOH, NaHCO3, giemsa stain, 
trypan blue and colchicine were obtained from sigma. Fetal bovine 
serum (FBS), antibiotic solution (penicillin/streptomycin, 
amphotercin-B), Dulbecco phosphate buffer saline (DPBS) 
ampicillin, tetracycline, nutrient agar from himedia. Agar (BD falcon), 
nutrient broth (oxoid), crystal violet, glacial acetic acid, methanol 
(Merck) [15].     
Metabolic activation system (Rat liver S9 fraction)  
In vitro assays were conducted both in the presence (+S9) and 
absence (-S9) of metabolic activation system. These test systems 
does not contain the enzyme systems which are generally present 
in mammals to metabolize pro-mutagens to active electrophilic 
metabolites able to react with DNA. Sometimes, these pro-
mutagens act together with a mammalian enzyme system and can 
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produce mutagenic metabolites. So, it is necessary to enrich with 
external metabolic activation system that is post mitochondrial 
fraction (S9) [15]. Rat liver S9 fraction was obtained from Molecular 
Toxicology, NC 28607, USA and stored at -80°C. S9 fraction was 
supplemented with essential cofactor mixture and used at a final 
concentration of 10% v/v (Ames) and 2% v/v (cell gene mutation 
and chromosomal aberration test ) [16].            
Preparation of drug  
Lower non cytotoxic and non mutagenic concentrations of quercetin 
was selected for antimutagenicity /adaptive response, whereas the 
mutagenicity of quercetin and reference standards selected for the 
test has been demonstrated in author’s laboratory for dose 
selection.    
A stock solution of quercetin and reference mutagens was prepared 
in DMSO and stored at -200C. The varying concentrations of 
quercetin was used in Ames test (0.5mg/plate), cell gene mutation 
and chromosomal aberration test (10µg/ml of culture medium) and   
micronucleus test (500mg per kg. b.wt in 0.5% Caboxy methyl 
cellulose), for evaluation of its antimutagenicity/adaptive response.     
 
Bacterial reverse mutation (Ames) test 
 
The Salmonella typhimurium bacterial strains TA 1537, TA 98, TA 
100 and TA 102 were obtained from Molecular Toxicology. INC, 
Boone. NC 28607, USA and used. Bacterial culture disc was added 
to 10ml oxoid nutrient broth and incubated for 15 hours at 37oC. 
After incubation bacterial cell count was adjusted to 1-2 x 109/ml 
with oxoid nutrient broth and used for the assay. Study was 
conducted both in the presence and absence of metabolic activation 
system.S9 mix (10%v/v) was used for the treatment in the presence 
and phosphate buffer saline was used in the absence of metabolic 
activation system.             
Ames test was performed by following pre-incubation method [15, 
17] for the evaluating antimutagenicity of quercetin. 100µl of 
quercetin (0.5mg in DMSO), 100µl of Salmonella thphimurium test 
strain (1-2 x 109/ml) and 100µl of positive mutagen and 0.5ml of 
phosphate buffer saline (PBS) or S9 mix (10%v/v) was added to 
glass tube and incubated for 20-30 min. at 37oC in water bath. After 
incubation culture mixture was added to 2 ml top agar tube and 
poured on Minimal Glucose Agar (MGA) plates. Triplicate plates 
were used for each concentration. Plates were incubated for 48 
hours at 37oC and colonies were counted manually.    
Positive mutagen 2-aminoanthracene, benzo (a) pyrene, 
bendamustine hydrochloride, cyclophosphamide monohydrate, 
hydralazine and etoposide were applied in the presence and 9-
aminoacridine, sodium azide, 2-nitrofluorene, hydralazine, 
etoposide, methyl methane sulphonate were applied in the absence 
of metabolic activation system. However hydralazine and etoposide 
were applied both in the presence and absence of metabolic 
activation system. Based on mutagenic response demonstrated in 
author laboratory specific test stains were selected for each 
mutagen. 
 
Table 2:  Quercetin antimutagenicity in Ames test using salmonella typhimurium strains 
Strain Absence of metabolic activation (-S9) Presence of metabolic activation (+S9) 
 NC Mutagen Quercetin 
+Mutagen 
% IM  NC Mutagen Quercetin 
+Mutagen 
    %IM 
TA 1537 8 208 324 Nd 8 Nt Nt Nt 
TA 98 23 662 552 16.62 27 884 116 86.88 
TA 100 108 
108 
1748 882 49.55* 125 1020 1203 Nd€ 
766 413 46.08^  500 136 72.70£ 
TA 102 296 980 579 40.92# 311 812 826 Nd¥ 
900 984 Nd$ 900 1115 Nd^ 
862 708 17.87^ 1178 894 24.11$ 
      
NC-Negative control, %IM-inhibition of mutagenicity, Nd-Not detected, Nt-Not tested. 
Mutagen (-S9): TA 1537-9 Amino acridine (50µg/plate), TA 98-2Nitro fluorine (7.5µg/plate), TA 100-*Sodium azide (5µg/plate), TA 102-#Methyl 
methane sulphonate (10µg/plate), $Etoposide(5mg/plate), ^Hydralazine(625µg/plate).  
Mutagen (+S9): TA 98-Benzo (a)pyrene (5µg/plate), TA 100-€2Amino anthracene (10µg/plate), £Cyclophosphamide monohydrate (10µg/plate), TA 
102-¥Bendamustine hydrochloride (5mg/plate), $Etoposide (5mg/plate).%IM calculation: 1-[Colonies in quercetin+mutagen plate/colonies in 
mutagen plate] x100. [7]. 
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Chromosomal aberration test (CAT)   
CHO-K1 cells (ATCC No. CCL-61) were used from Palamur 
Biosciences Pvt. Ltd., cell line repository. Cells were cultured in 
Hams F12 K medium supplemented with 10% fetal bovine serum, 
penicillin (100IU/ml), amphotericin B (0.25µg/ml) and streptomycin 
(100µg/ml) and incubated in a CO2 incubator at 37
oC and 5% CO2. 
Culture was maintained by sub-culturing with 2-3x105cells/ml per 
each passage in a 75cm2 culture flasks (Nunc 156367).   
Monolayers of culture (2-3 x 105/ml) were exposed to 10µg/ml of 
quercetin. After 12 hours (equal to one generation time) incubation 
10µl of reference mutagens were added to the culture medium. 
Benzo(a)pyrene (5µg/ml) and cyclophosphamide monohydrate 
(25µg/ml) was tested in the presence (+S9) and methyl methane 
sulphonate (20µg/ml) in the absence of metabolic activation system.  
Cells were incubated for further 4 hours, after incubation cells were 
washed with Dulbecco’s phosphate buffer saline and fresh culture 
medium was added. Cells were further incubated for 1.5 normal cell 
cycle lengths (18hours) from the beginning of treatment. At 16th 
hour, 0.4µg colchicine (metaphase arresting agent) was added to 
each 1ml of culture. After 18hours incubation, cells were collected 
by trypsinisation and subjected to hypotonic treatment (8ml of 
0.075M KCL solution). During hypotonic treatment tubes were 
incubated in a water bath at 37oC for 25 min; centrifuged and the 
pellet was fixed in Carnoy’s fixative (3:1 methanol: acetic acid). The 
cell pellet was prepared again and resuspended in a small volume 
of fixative. The cell suspension was dropped on to cleaned chilled 
slides and stained with 5% giemsa stain and mounted with DPX 
mount. Four slides were prepared from each concentration. 300 well 
spread metaphase cells from each concentration (include replicate 
1 & 2) were observed for structural chromosomal aberrations under 
100x objective of microscope. All the slides were coded prior to the 
screening [18, 19] and decoded after slide scoring. 
 
Table 3: Adaptive response and antimutagenicity in chromosomal aberration test (CAT) 
Absence of metabolic activation system (-S9) 
Dose (µg/ml) %MI % Aberrant cells Reduction in % 
Aberrant cells 
Negative control (0.0) 5.4 1.00 NA 
Quercetin (10) 5.0 1.67 NA 
Methyl methane sulphonate (20) 3.1 14.0 NA 
Quercetin+ Methyl methane sulphonate 
(10+20) 
3.6 10.33 28.2 
Presence of metabolic activation system (+S9) 
Dose (µg/ml) %MI % Aberrant cells Reduction in % 
Aberrant cells 
Negative control (0.0) 5.8 1.33 NA 
Quercetin (10) 5.2 2.00 NA 
Benzo(a)pyrene (5) 2.8 16.00 NA 
Cyclophosphamide monohydrate (25) 3.6 18.67 NA 
Quercetin+ Benzo(a)pyrene (10+5) 3.4 10.00 40.9 
Quercetin+ Cyclophosphamide 
monohydrate (10+25) 
3.6 12.33 36.7 
Mitotic index was calculated by formula: No. of metaphase cells/Total number of cells counted (1000 cells) x 100. 
%Reduction calculation: N. Aberrant cells by the mutagen – N. Aberrant cells by quercetin+mutagen / N. Aberrant 
cells by the mutagen- N. Aberrant cells in negative control*100., [19]. N. - number of, %MI-mitotic index, NA-Not 
applicable. 
 
Cell gene mutation test (CGM) using L5178Y TK+/- 
mouse lymphoma cells 
 
L5178Y TK+/- cells (ATCC No. CRL-9518) were used from Palamur 
Biosciences Pvt. Ltd., cell line repository. Cells were cultured in 
RPMI 1640 medium supplemented with 10% fetal bovine serum, 
penicillin (100IU/ml), amphotericin B (0.25µg/ml) and streptomycin 
(100µg/ml) and incubated in a CO2 incubator at 37
oC and 5% CO2. 
Culture was maintained by sub-culturing with 2-3x105cells/ml per 
each passage in a 25cm2 culture flasks.   
Suspensions of cells (5-6x105/ml) were treated with 10µg/ml of 
quercetin. After 13 hours incubation 10µl of reference mutagens 
were added to the culture medium. Benzo(a)pyrene (5µg/ml), 
bendamustine hydrochloride (20µg/ml) and cyclophosphamide 
monohydrate (20µg/ml) was tested in the presence (+S9) and 
methyl methane sulphonate (20µg/ml) and etoposide (0.2µg/ml) in 
the absence of metabolic activation system.  Cells were incubated 
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for further 4 hours and the treatment medium was replaced with 
fresh culture medium by centrifugation (1200 rpm for 10 min.). After 
treatment cells were allowed for mutation expression for 2 days and 
plated for cloning efficiency and trifluorothymidine (TFT) resistance. 
During expression, cells were sub-cultured to maintain 5-6 x 
105cells/ml. Cell count was adjusted to 8 cells/ml of complete 
medium for viability plating and 10000 cells/ml of complete medium 
with TFT (3µg/ml) for TFT resistance colonies to calculate mutation 
frequency. The cells (0.2ml/well) were added to 96 well plates and 
incubated for 12 days in a CO2 incubator and colonies were 
counted under inverted microscope (Olympus CKX41SF) [20]. 
 
Table 4: Adaptive response and antimutagenicity in cell gene mutation test (CGM) 
   
Absence of metabolic activation system (-S9)   
Dose (µg/ml)  %Cloning efficieny (CE)  Mutation frequency (MF) %Reduction in 
MF 
Negative control (0.0) 81.65 54.99 NA 
Quercetin (10) 53.94 88.62 NA 
Methyl methane sulphonate (20) 30.96 393.41 NA 
Etoposide (0.2) 22.02 289.74 NA 
Quercetin+ Methyl methane 
sulphonate (10+20) 
35.39 257.70 40.1 
Quercetin+ Etoposide (10+0.2) 24.37 238.00 22.0 
Presence of metabolic activation system (+S9)    
Dose (µg/ml) %Cloning efficieny  
(CE) 
Mutation frequency (MF) %Reduction in 
MF 
Negative control (0.0) 85.36 
 
73.10 
 
NA 
Quercetin (10) 64.87 
 
84.78 
 
NA 
Benzo(a)pyrene (5)  33.69 
 
584.45 
 
NA 
Cyclophosphamide monohydrate  
(25) 
  
35.96 
 
515.85 
 
NA 
Bendamustine hydrochloride (20) 34.25 
 
476.79 
 
NA 
Quercetin+Benzo(a)pyrene (10+5) 38.92 
 
347.64 46.3 
Quercetin+ Cyclophosphamide 
monohydrate (10+25) 
40.16 319.97 44.2 
Quercetin+ Bendamustine 
hydrochloride (10+20) 
43.98 487.95 Nd 
%cloning efficiency: -ln P(0)/1.6x100, Mutation frequency = (PE mutant/PE viable) x 106., [16].  
%Reduction in MF calculation: MF by the mutagen – MF by the mutagen+quercetin / MF by the mutagen- MF in negative 
control*100.  MF-mutation frequency, NA-Not applicable, Nd-Not detected.   
 
Mice bone marrow micronucleus test 
The experiments were performed on Swiss albino mice (8 weeks 
old) with weight variation ± 20% of the mean weight of each sex. All 
experimental procedures were approved by the Institutional Animal 
Ethics Committee. The mice were housed in separate 
polypropylene cages in experimental room. All the animals were 
maintained at 22 ± 2°C and the relative humidity set at 40-70% with 
a 12:12-hour’s light-dark cycle. They were fed with standard pellet 
feed and UV sterilized water ad libitum. Mice were acclimatized in 
the experimental room for five days before beginning the 
experiment. 
Grouping and treatment   
Swiss albino mice were divided into six groups viz., G1 (Vehicle 
control), G2 (Adaptive dose; quercetin), G3 (challenge dose 1:  
benzo(a)pyrene), G4 (challenge dose 2: cyclophosphamide 
monohydrate), G5 (quercetin+benzo(a)pyrene) and G6 
(quercetin+cyclophosphamide monohydrate). Each group 
comprises of ten animals (5M+5F: females were nulliparous and 
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non-pregnant). G1 mice were treated with 0.5% carboxy methyl 
cellulose. G2 animals were treated with 500mg quercetin (oral), G3 
animals with 200mg benzo(a)pyrene (intraperitoneal) and G4 
animals with 40mg cyclophosphamide (oral) per kg b.wt. Group 5 
and 6 animals were pre-treated with 500mg quercetin for 3hours 
before the administration of benzo(a)pyrene and cyclophosphamide. 
Doses volume was 1.0ml per 100g body weight at once for all 
groups. All the animals were sacrificed by CO2 asphyxiation at 
24hours following treatment. Bone marrow was collected and slides 
were prepared, stained and observed under microscope for micro 
nucleated polychromatic erythrocytes (MNPCE). A minimum of 
2000 PCE were screened per each animal and the % micro 
nucleated polychromatic erythrocytes (%MNPCE) was calculated 
[21, 22]. 
 
Table 5: Adaptive response and antimutagenicity in mice bone marrow micronucleus test 
Group Sex Mean     MN 
PCE 
Total PCE 
counted for MN 
% MN PCE 
Group 1                     
(vehicle control) 
 
Male 5.0 10037 0.25±0.05 
Female 4.8 10037 0.24±0.02 
Group 2 
(quercetin 500mg/kg b.wt.) 
 
Male 7.2 10046 0.36±0.05 
Female 6.6 10045 0.33±0.06 
Group 3 
(BP 200mg/kg b.wt.) 
 
Male 83.4 10037 4.15±0.38 
Female 84.6 10052 4.21±0.38 
Group 4 
(CP 40mg/kg b.wt.) 
 
Male 71.8 10064 3.57±0.24 
Female 68.4 10038 3.41±0.52 
Group 5 
(Q+BP 500+200mg/kg b.wt.) 
 
Male 54.0 10031 2.69±0.19 
Female 51.6 10076 2.56±0.29 
Group 6 
(Q+CP 500+40mg/kg b.wt.) 
Male 40.0 10114 1.98±0.16 
Female 42.6 10048 2.12±0.19 
 
Statistical analysis 
Graph pad Prism 6.0 software was used for statistical analysis. 
Fisher’s exact test was used to check the statistical significant (p 
value <0.05) difference between mutagen and in combination 
treatment groups in chromosomal aberration test. In Mice bone 
marrow micronucleus test, unpaired t-test was followed to check the 
statistical significant (p value <0.05) difference between mutagen 
and in combination treatment groups (quercetin+mutagen).        
Results 
Results of in vitro studies are the average of two individual 
experiments.     
Bacterial reverse mutation (Ames) test 
Ames test was performed according to the procedure detailed in 
methods; the colonies were counted manually and % inhibition of 
mutagenicity (IM) was calculated by formula detailed in table 2. The 
varied response of quercetin was observed against different types 
of mutagens used in the test. Quercetin did not show any 
antimutagenic activity against 9 aminoacridine, 2 amino anthracene, 
bendamustine hydrochloride and modest effect against 2 
nitrofluorine, hydralazine and etoposide; whereas a significant 
inhibition  of mutagenicity (%IM) due to quercetin antimutagenicity 
was observed against sodium azide, methyl methane sulphonate, 
benzo(a)pyrene and cyclophosphamide monohydrate. Significant 
inhibition of mutagenicity (%IM) was observed against hydralazine 
in the absence of metabolic activation system and the same effect 
was not observed in the presence of metabolic activation system.        
Chromosomal Aberration Test (CAT)   
Results of CAT were shown in table 3. Initially 1000 cells per each 
slide were counted for metaphase cells to calculate mitotic index 
because mitotic index is the major constrain for calculating 
cytotoxicity. A significant reduction in percent mitotic index was 
observed with selected mutagens both in the presence and 
absence of metabolic activation system when compared with 
negative control. However cytotoxicity due to quercetin treatment 
was not observed, while a slight reduction in cytotoxicity was 
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observed in combination of mutagen+quercetin when compared 
with mutagen alone, though it is statistically insignificant.    
For each dose group 300 well spread metaphases with equally 
divided in two replicates with 20±2 chromosomes were observed for 
structural chromosomal aberrations. Mean % aberrant cells 
(excluding gaps) were considered for results evaluation. A 
significant reduction in percent aberrant cells was observed in 
selective combination of mutagen with quercetin, though the rate of 
quercetin induced reduction rate was little high in the presence of 
metabolic activation system (with benzo(a)pyrene and 
cyclophosphamide monohydrate) than in the absence (methyl 
methane sulphonate). However there was no significant difference 
in percent aberrant cells of quercetin when compared with negative 
control.   
Cell gene mutation test (CGM)  
After 12 days of incubation 96 well plates were observed for 
colonies (cloning efficiency/viability and TFT resistance) under 
inverted microscope and unaided eye manually, reported in table 4. 
Both small and large colonies were considered for evaluation of 
results. Cloning efficiency was calculated to determine the 
cytotoxicity of selected test compounds by comparing with negative 
control. While in TFT plates an increase in the number of small 
colony was observed because of clastogenic damage induced by 
the test mutagens.    
A decrease in mutation frequency (%RMF) was observed in 
quercetin+mutagen combination when compared with mutagen 
alone, both in the presence (+S9) and absence (-S9) of metabolic 
activation system, though the effect is varied. The combination of 
quercetin+etoposide (in -S9) exhibited only slight %RMF, whereas 
%RMF was not observed with bendamustine hydrochloride (in+S9).  
Significant difference/decrease in %RMF was observed with 
remaining combinations (Q+MMS, Q+BP, Q+CP). The varied 
results strongly indicate that the adaptive response of quercetin is 
selective towards certain alkylating agents when tested in 
eukaryotic test systems in vitro. However quercetin treatment alone 
did not result significant increase in mutation frequency when 
compared to negative control.  
Mice bone marrow micronucleus test 
The incidence of micro nucleated polychromatic erythrocytes 
(MNPCE) was counted in 2000 PCE from the bone marrow sample 
of each animal (detailed in table 5). A significant increase in 
%MNPCE was observed in animals of both sex treated with 
mutagen alone (G3, G4), while there was no significant difference in 
%MNPCE was observed in negative control (G1) and quercetin 
treated animals (G2). However a significant reduction in %MNPCE 
was observed in animals treated with a combination of quercetin 
and mutagens such as; benzo(a)pyrene (G5) and 
cyclophosphamide monohydrate (G6).      
Discussion   
Genetic toxicology tests are usually employed for the screening of 
new chemical entities and natural compounds in preclinical industry 
for the safety assessment and for the identification of antimutagenic 
and anticarcinogenic potential, as well as for revealing their mode of 
action. In vitro assays with prokaryotic and eukaryotic test systems 
are performed in combination with mammalian enzymes, this can 
provide the information about the metabolic activation system or 
detoxification that an agent may undergo in vivo. Hence we 
emphasise that the combination of different test systems with range 
of mutagens applied herein are important to gain explicit knowledge 
on the adaptive response and antimutagenicity of quercetin.          
Quercetin mutagenicity was extensively reported in various in vitro 
mutagenicity assays and the same results were observed in the 
author’s laboratory, long-term in vivo toxicity and carcinogenicity 
studies are failed to show the existence such correlation. Structure 
of the flavonoid ring; quercetin, kaempferol is responsible for their 
mutagen city [23]. Quercetin can bind directly to DNA and this 
contact may be one of the mechanism of in vitro mutagenicity and 
also strong mutagen in bacteria [24,25]. Quercetin is a pro-oxidant 
can oxidise nuclear envelope lipids and cause DNA strand breaks 
[26]. Based on these study results non-cytotoxic and non-mutagenic 
concentrations of quercetin was applied in the antimutagenicity and 
adaptive response assays. Mutagens that trail different 
mutagenic/DNA damaging pathways including; oxidation and direct 
DNA adduct or cross linking, alkylation, free radicals formation were 
selected to demonstrate the quercetin mode of action.      
Quercetin shown considerable antimutagenicity against alkylating 
agent (CP, MMS), pro-mutagen and DNA adduct (benzo(a)pyrene) 
and direct damaging agent (sodium azide) in Ames test. Similar 
results were observed in cell gene mutation test using 5178Y TK+/- 
cells (CP, BP); make clear that quercetin protective role is closely 
similar in both prokaryotic and eukaryotic test systems against the 
same mutagens.     
In chromosomal aberration test, significant reduction in 
benzo(a)pyrene (p value:0.03) and cyclophosphamide (p 
value:0.04) induced mutagenicity was observed  in the presence of 
metabolic activation system where as the moderate effect was 
observed against methyl methane sulphonate induced mutagenicity 
in the absence of metabolic activation system. Defence against 
oxidative damage is the extensively reported attributes of 
polyphenols and may be the reason for using as dietary 
supplements. CYPA1 activity is especially needed in the 
mutagenicity/metabolism of pro-mutagens like 2 amino anthracene 
and benzo(a)pyrene. Concentration dependent inhibition of rat 
microsomal CYP1A1 activity by quercetin was well reported [27] 
and this is one of the mechanisms behind benzo(a)pyrene reduced 
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mutagenicity. Quercetin is an excellent free-radical scavenging 
antioxidant, protects against lipid peroxidation, chelates metal ions 
and forms inert complexes to prevent formation of hydroxyl radicals. 
These biological reactions strongly corroborate for its antimutagenic 
activity against free radical producing alkylating agent’s 
benzo(a)prene and cyclophosphamide monohydrate.    
Quercetin showed a clear antimutagensis effect against the direct 
DNA damaging agents; sodium azide and methyl methane 
sulphonate, shown protective role against sodium azide induced 
point mutations in Salmonella strain TA 100 and methyl methane 
sulphonate induced point mutations in thymidine kinase locus of 
L5178Y TK+/- cells, transitions/transversion mutations in TA 102 
strain that detects DNA oxidative damage and clastogenicity in both 
in vitro and in vivo assays. This mechanism of protection may be 
due to the DNA repair genes expression, trap mutagenic 
compounds by direct binding and prevent DNA damage. Alba et al., 
confirmed the presence of the DNA-repair ogt-gene is essential for 
the antimutagenic action of Rhoeo discholor plant extracts signifying 
that these extracts may progress the O6 alkylguanine DNA 
alkyltransferase DNA repair enzymes activity. Furthermore 
mezougg et al., reported the extracts of different plants flavonoids 
could be acting as desmutagens; preventing DNA damage by direct 
binding to alkyl radicals [28, 29]. One more mechanism behind the 
protective role against these direct acting mutagens is the free 
radical scavenging and greatest antioxidant activity of quercetin.                       
Considering in vitro study results, quercetin protective role via 
adaptive response was tested in bone marrow chromosomal 
aberration in mice against BP and CP induced mutagenicity. 
Significant reduction in %micro nucleated polychromatic 
erythrocytes was observed in combination of quercetin and 
mutagen in either sex of animals. The observed effect was (p value: 
0.001) closely similar to both tested mutagens indicates quercetin 
may decrease the catalysis of nitrosoylation of DNA alkylating 
agents BP and CP. Like many plant flavonoids quercetin may 
upregulate the glutathione S-transferase (GST) enzyme activity 
enhance the excretion of oxidising species or induce metallothionein 
an antioxidant enzymes. Quercetin may also inhibit the uptake of 
mutagens like benzo(a)pyrene [30] and also significantly prevent the 
formation of DNA adduct which was demonstrated in PhIP (2-
amino-1-methyl-6-phenylimidazo [4,5-b] pyridine)-DNA adduct 
formation studies in rat colon with many of plant polyphenols 
including quercetin [31].   
Quercetin may induce cytotoxicity in cancer cells through multiple 
routes of action. It is plausible that quercetin interacts with DNA 
directly (DNA intercalation), and could be one of the mechanisms 
for inducing programmed cell death in both, cancer cell lines and 
tumor tissues by inducing the intrinsic apoptotic pathways. It is also 
shown to induce cell cycle arrest in S phase in various cancer cell 
lines. The several data consistently support the ability of quercetin 
as an effective anticancer agent because of low toxicity to normal 
tissue even at the concentrations that are highly detrimental to the 
cancer cells. The precise nature of quercetin to exhibit distinct 
biological effects on cancer and normal cells is the most promising 
feature of a chemical compound in the field of anticancer research.    
Conclusion  
Results of the current study indicate that quercetin demonstrated 
strong protective role against range of mutagens via majority of 
antimutagenicity and adaptive response mechanisms in a 
combination of in vitro and in vivo test systems, which could be the 
rationale for its potent anticancer activity. It is also evident from the 
results that the distinct antimutagenic activity of quercetin against 
mutagens of varied type may partly explain the suitability of 
quercetin as an anticancer agent against particular cancer types.  
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